It is widely accepted that infection control, advanced diagnostics, and novel therapeutics are crucial to mitigate the impact of antibiotic-resistant bacteria. The role of global, national, and regional surveillance systems as part of the response to the challenge posed by antibiotic resistance is not sufficiently highlighted. We provide an overview of contemporary surveillance programs, with emphasis on gram-negative bacteria.
INTRODUCTION
The introduction of penicillin and sulfonamides into clinical practice in the middle of the twentieth century revolutionized the treatment of bacterial infections, offering remedy for diseases that were previously lethal. This power did not rest in the hands of a few skilled practitioners in wealthy societies, but became widely available. It is not an exaggeration to assert that antimicrobial chemotherapy, as well as improved sanitary conditions and vaccination, largely explains trends toward longer life expectancy around the world. Antibiotic treatment and prophylaxis of bacterial infections remain essential to sustain advances in neonatal care, surgery, organ transplantation, and cancer chemotherapy. The emergence of bacteria resistant to all or most existent antibiotics, especially in the realm of gram-negative bacteria, constitutes a crisis: a return to the preantimicrobial era is a real possibility in the twenty-first century [1 && ]. In order to stem this crisis, a worldwide response is urgent to develop new agents that fill unmet therapeutic needs, to improve the use of currently available antibiotics, and to prevent and control the transmission of bacteria resistant to antibiotics [2] . Such actions can only be guided by reliable epidemiological information about the prevalence and impact of resistant bacteria in different settings. Although antibiotic resistance is a universal public health concern, great gaps remain in our current understanding of the magnitude of the problem. Improved surveillance of antibiotic resistance in bacteria is necessary to fill those gaps [3] . The
WHO: ANTIBIOTIC RESISTANCE SURVEILLANCE ON A GLOBAL SCALE
The WHO recently issued a comprehensive report on antimicrobial resistance surveillance, which intended to provide a detailed picture of the current state of surveillance globally [4 && ]. Data from 129 member countries were sought for a selected set of nine bacteria-antibacterial drug combinations (Table 1) . Overall, 114 countries provided information regarding at least one of nine bacteria-antibacterial drug combinations; only 22 countries contributed data for all nine combinations. The paucity and inconsistency in the availability of data reveal the lack of surveillance infrastructure at the national level that can be drawn upon to collect information from individual member countries. Most of the country-level data originated from the European Region and the Region of the Americas, where regional surveillance efforts have been more successful, and less so from Asia and Africa. Furthermore, data sources were biased toward bacterial infections associated with healthcare at the expense of community-acquired infections. Overall, the lack of a global consensus on the methodology and data collection was acknowledged as a major obstacle for effective surveillance of antibiotic-resistant bacteria.
The report features WHONET (http://www. whonet.org), freely accessible software (created and maintained by J. Stelling and T.F. O'Brien) that is widely used as a common platform for antibiotic resistance data collection, management and sharing, and serves as a strategy to facilitate global surveillance of antimicrobial resistance, including low-and middle-income countries [5] .
EUROPE: ADVANCED INTEGRATED SURVEILLANCE
The European Antimicrobial Resistance Surveillance Network (EARS-Net) is a multicountry surveillance network that collects routine clinical antibiotic susceptibility data from national surveillance systems [6 && ,7] . The European Centre for Disease Prevention and Control (CDC) has hosted EARS-Net since 2010. Its charge is to document the emergence and dissemination of antibiotic-resistant bacteria in Europe, and to increase awareness among the citizenry, scientists, and public health authorities. Focused scientific papers and maps, graphs and tables from yearly reports are available through a web-based data query tool. There are two other
KEY POINTS
Bacterial resistance to antibiotics is a major global health threat. Systematic, comprehensive surveillance is essential to determine the magnitude of the problem, and inform local, regional, national and global interventions to address the challenge of resistance.
The framework of antibiotic-resistance surveillance needs to be adjusted to meet the mission and capacity of supranational, national and regional public health agencies, the resources of healthcare facilities from wealthy and emerging economies, and the objectives of researchers and healthcare providers.
Advances in bioinformatics and genomics will render surveillance of bacterial resistance to antibiotics more effective at preventing and controlling infections, revealing insights into the underpinnings of antibiotic resistance, and improving the outcomes of patients. ]. EARSNet also cooperates with the European Committee on Antimicrobial Susceptibility Testing to establish guidelines and quality assurance activities among member countries [11] .
The most recent reports from EARS-Net reveal a continuous increase between 2010 and 2013 in resistance to third-generation cephalosporins in Klebsiella pneumoniae and Escherichia coli mediated by extended-spectrum beta-lactamases, with coresistance to fluoroquinolones and aminoglycosides. Carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. were common. Carbapenem-resistant K. pneumoniae occurred in high proportions in Greece (60%), Italy (40%), and Romania (30%) but remained infrequent in the rest of the European countries [6 && ]. The European CDC, the European Food Safety Authority, and the European Medicines Agency carried out an integrated analysis on the consumption of antibiotics in food-producing animals and humans, and its impact on the occurrence of antibiotic-resistant bacteria [12 && ]. In most of the surveyed countries, the average consumption of antibiotics, including fluoroquinolones and cephalosporins, was lower in food-producing animals than in humans. Correlations were observed between antibiotic consumption and resistance prevalence in animals, in humans, and from animals to humans, for Campylobacter and E. coli resistant to flouroquinolones, cephalosporins, and tetracyclines. Molecular characterization of bacterial isolates from human and food-producing animals will be necessary to understand the underpinnings of those associations. These first-integrated analyses demonstrate the need to refine existing surveillance systems in order to obtain more detailed information on antibiotic consumption. Similarly, more detailed information is needed on the prevalence of antibiotic-resistant bacteria in foods originating from animals and from different locations, and further understanding of the relationship between antibiotic-resistant bacteria and animal and human commensal flora.
The surveillance systems delineated above contain limited data regarding antibiotic-resistant bacteria and antibiotic consumption among children. The Antibiotic Resistance and Prescribing in European Children project, created to fill that void, reveals that the profile of antibiotic resistance in bloodstream isolates from children differs from those reported by EARS-Net. This finding indicates that caution should be used when generalizing data from surveillance to special populations [13 & ].
ISRAEL: FROM SURVEILLANCE TO ACTION
The experience of Israel dealing with carbapenemresistant Enterobacteriaceae (CRE) illustrates how findings from surveillance efforts ultimately can lead to interventions that prevent and control the emergence of antibiotic-resistant bacteria. After the initial identification of Klebsiella pneumoniae carbapenemase (KPC) in carbapanem-resistant K. pneumoniae isolates from Tel-Aviv hospitals in 2005, a nationwide outbreak was documented in 2006. Detailed molecular characterization revealed that the outbreak was caused by a clone of KPC-3-producing K. pneumoniae related to the international strain identified by multilocus sequence typing as sequence type ST258 [14] . In 2007, the Israel Ministry of Health initiated a nationwide intervention to respond to the threat that hyperepidemic, extensively drug-resistant K. pneumoniae posed to Israeli hospitals and its healthcare system. Data played a central role in informing and monitoring the success of the interventions at individual hospitals, which included carrier isolation, patient and staff cohorting, active search for cases, and standardized procedures for microbiologic detection. Coordination and tracking of the response depended on a national network of communications that facilitated reporting and data-sharing, as well as onsite examinations of procedures at healthcare facilities. These actions achieved a 10-fold reduction in the transmission of CRE in the acute care setting [15 && ]. This nationwide intervention also included postacute care facilities, recognized as an important reservoir of antibiotic-resistant bacteria, where enhancement of infection control measures led to a reduction in the prevalence of CRE [16] . Ongoing molecular characterization in postacute care facilities confirms the predominance of ST258 KPC-producing K. pneumoniae, and has permitted the detection of other mechanisms of carbapenem resistance, namely OXA-48 and New Delhi Metallo-beta-lactamase (NDM-1), imported from neighboring countries in the Middle East [17] . Surveillance activities extended into the community have led to the exclusion of transmission in that setting [15 && ]. The Israeli experience is a prime example of the effective translation of research into public health objectives that has improved the safety of hospitalized patients in that country. Table 2) .
UNITED STATES: REGIONAL SURVEILLANCE EFFORTS TAKE CENTER STAGE
Surveillance of antibiotic resistance among bacteria causing HAIs through the NHSN also describes increasing multidrug resistance and carbapenem resistance in gram-negative bacteria from a large proportion of facilities [19] . A more detailed assessment of the status of CRE infections in the United States as of 2012 was possible by supplementing information derived from the NSHN with data collected through the multisite resistant gram-negative bacilli surveillance initiative (MuGSI), a population-based surveillance project conducted by the U.S. CDC Emerging Infections Program, and from The Surveillance Network, an electronic surveillance database of antibiotic resistance encompassing several hundred microbiology laboratories across the country [20, 21] . Approximately 4% of hospitals reported infections due to CRE and as many as 18% of long-term acute care hospitals (LTACHs). The proportion of Klebsiella sp. resistant to carbapenems averaged 10%, occurring mostly in patients with substantial healthcare exposures [22] . These findings served to increase awareness and have motivated public health action to counter the dissemination of CRE in U.S. healthcare facilities [23] .
Important efforts to advance surveillance of CRE and other antibiotic-resistant bacteria in the United States have occurred at the regional level. & ]. In the region around Chicago, Illinois, a multidrugresistant organism surveillance network involving 25 short-stay acute care hospitals and seven LTACHs served to carry out a single-day prevalence survey demonstrating CRE in 30% of patients from LTACHs, and only in 3% of patients from acute care hospitals [30] . 
ANTIMICROBIAL RESISTANCE MONITORING AND RESEARCH PROGRAM: A MODEL FROM THE U.S. DEPARTMENT OF DEFENSE
The Antimicrobial Resistance Monitoring and Research (ARMoR) program was established by the U.S. Department of Defense in 2009 as a comprehensive surveillance program including the participation of epidemiologists, bioinformaticists, microbiologists, and healthcare providers. It features centralized data gathering, taking advantage of the existing electronic medical record, as well as detailed molecular characterization of multidrug-resistant organisms in a central laboratory. A fundamental aspect of the ARMoR program is the transmission of laboratory and surveillance data back to participating hospitals through periodic reports on target bacteria. Similarly, these reports are communicated to leaders and policy makers within the healthcare facilities and the organization. Although it is challenging to establish a causal effect, there has been a significant decrease in the prevalence of CRE after the implementation of the ARMoR program. Indeed, this program serves as a model for comprehensive programs to combat antimicrobial resistance to be adopted by other healthcare organizations in the United States [33 && ].
A NATIONAL PLAN TO STRENGTHEN SURVEILLANCE
Recently, the U.S. President CRE issued the National Action Plan for Combating Antibiotic-Resistant Bacteria, which features the strengthening of surveillance as a fundamental component. The plan contemplates routine reporting of antibiotic use and resistance data to the NHSN by most U.S. hospitals, as well as monitoring of antibiotic use and resistance along the continuum of food production, from farms to processing plants to supermarkets. The National Action Plan also calls for the creation of a regional public health laboratory network offering genetic characterization of antibiotic-resistant bacteria.
A 'one-health' approach, where the health of humans is recognized to depend on the wellbeing of animals and the conservation of the environment, is emphasized throughout the plan [34 && ]. Therefore, one of the goals is to integrate data from the NHSN, Emerging Infections Program, and the National Antimicrobial Resistance Monitoring System for foodborne and enteric bacteria, with data from the National Animal Health Monitoring System, the National Animal Health Laboratory Network, and the Veterinary Laboratory Investigation and Response Network. An additional goal is to develop laboratory-based surveillance to detect and monitor antibiotic resistance in key animal and human foodborne pathogens in collaboration with the WHO and the World Organization for Animal Health.
UNDER-RESOURCED COUNTRIES: FILLING THE GAPS IN SURVEILLANCE
Important gaps in the surveillance of antibioticresistant bacteria are evident in developing countries. Ironically, it is often in these countries where the challenge posed by resistant bacteria is the greatest, threatening to erode the important contribution of antibiotics to the health of the population. A noteworthy example that illustrates the need and potential impact of surveillance systems in combating antibiotic resistance is provided by Viet Nam. In this Southeast Asian country with more than 90 million inhabitants, gram-negative bacteria reach high levels of resistance (40% of extended-spectrum beta-lactamase-producing Enterobacteriaceae among hospitalized patients; presence of NDM-1 in patients and the hospital environment; and high carbapenem resistance rates in P. aeruginosa and A. baumannii). This is likely due to limited infection control and diagnostic capabilities, and to widespread overuse and misuse of antibiotics [35] .
To respond to this challenge, an ambitious program is underway that aims to strengthen the country's ability to implement infection control and antimicrobial stewardship programs. The Ministry of Health of Viet Nam has committed to build a surveillance program to monitor hospital antibiotic use and resistance, community antibiotic use and resistance, and antibiotic use and resistance in animals, and to provide a reference laboratory and quality assurance mechanisms for local microbiology laboratories [35] . Additionally, Viet Nam Resistance is being implemented as a capacity-building initiative designed to equip 16 hospitals with the tools to perform self-sufficient antibiotic surveillance and carry out antimicrobial stewardship. Hospitals submit monthly data on antibiotic consumption, infection control surveillance, and susceptibility of bacterial pathogens (using WHONET); hospitals receive regular reports, which compare their performance to that of other hospitals [36] . These objectives and framework are eminently transferable to other developing countries, and compatible with Resolution 67.25 from the World Health Assembly that urged countries, especially low-and middle-income countries, to develop capacity to combat antimicrobial resistance through strengthened surveillance and laboratory capacity [37] .
Indeed, they resonate with a surveillance initiative undertaken in Colombia, a middle-income country in South America. Since 2003, the Centro Internacional de Entrenamiento e Investigaciones Médicas developed a surveillance project that now comprises 23 hospitals in 10 cities, with the objective of tracking antibiotic resistance among gramnegative bacteria. In the most recent 4-year period, a total of 38.048 bacterial isolates were analyzed using WHONET, demonstrating increasing trends in the proportion of multidrug-resistant bacteria. Detailed molecular characterization of resistance determinants and strain typing of carbapenem-resistant organisms was carried out in a central laboratory, revealing in the case of carbapenem-resistant K. pneumoniae, the coexistence of KPC-producing and Verona integron-encoded metallo-betalactamase (VIM)-producing isolates [38 & ]. Feedback on their respective data on antibiotic resistance, molecular mechanisms, and strain typing is transmitted to participating hospitals. These reports, in turn, help inform infection control and antimicrobial stewardship actions at the local level. Additionally, they provide insights into the molecular epidemiology of antibiotic-resistant gram-negative bacteria in Colombia, and permit comparisons to be drawn at the continental and global levels [39] [40] [41] .
CONCLUSION: CHALLENGES AND OPPORTUNITIESIN SURVEILLANCE
This review highlights models of surveillance for antibiotic-resistant bacteria around the world (Table 3 ). Notwithstanding their current limitations, these surveillance schemes remain an essential complement to better diagnostics, potential vaccines, and introduction of novel antibiotics active against resistant bacteria. Furthermore, the analysis of bacterial isolates through surveillance projects yields important insights into the transmission dynamics and mechanistic underpinnings of resistance. The threat posed by the emergence and dissemination of antibiotic-resistant bacteria demands the strengthening of current regional, national, and global surveillance systems.
The impact of surveillance can be improved by incorporating data on antimicrobial use and antibiotic resistance, as well as data from different components of healthcare. A 'one-health' approach, integrating multiple disciplines working locally, nationally, and globally to improve the health of people, animals, and the environment, is a paradigm very well suited to surveillance schemes. Existing surveillance systems are very limited in this regard. Another crucial shortcoming of antimicrobial resistance surveillance is that data are consigned in one-time or annual reports, and do not reflect an up-to-date assessment of antibiotic consumption and resistance. Antimicrobial resistance trend monitoring system (ARTEMIS), a pilot network of seven European healthcare institutions sharing data about drug resistance and consumption using a semantic web-based model, provides an example of how this problem can be overcome. Queries obtained within a few seconds provide real-time information about antimicrobial resistance that is accurate, comparable to data from EARS-Net. This or similar platforms can serve as the backbone of future multisite and multinational surveillance networks that allow rapid detection of emerging resistance to antibiotics, and guide immediate infection control and public health actions [42] . Also harnessing the power of bioinformatics, an alternative approach to monitor trends in antibiotic resistance proposes the use of automated semantic and scientometric analysis of PubMed entries. When the relationship between the introduction of novel antibiotic classes into the market and emergence of bacterial resistance was investigated, and compared with data from EARS-Net, only a partial correlation was observed between scientometric analysis and development of resistance. Nevertheless, insight was gained about the public health importance of certain resistance mechanisms [43 & ]. The application of genomic tools to the characterization of antibiotic resistance determinants and strains also promises to enhance surveillance. In this regard, the outbreak of carbapenem-resistant K. pneumoniae that occurred in 2011 at the U.S. National Institutes of Health Clinical Center provides an illustrative example. Whole-genome sequencing gave insights into the reasons why the epidemic progressed despite initial infection control measures, by revealing unexpected transmission routes [44] . In another analysis, long-read genome sequencing with full end-to-end assembly revealed that carbapenem resistance genes are located on a wide array of plasmids, with evidence of horizontal gene transfer between bacteria in the hospital environment [45 && ]. The integrated surveillance of antibiotic resistance, thus enhanced by genomics and bioinformatics, promises to overcome some of the obstacles we encounter in understanding the emergence of resistance, and to yield more 'precise' approaches to prevention, diagnostics, screening, and treatment that may preserve the benefits of antibiotics to individual patients and society [5] .
